Two Zolgensma patients die of liver failure
On August 11, 2022, Novartis reported the death of two Zolgensma patients from liver failure. Zolgensma (onasemnogene abeparvovec), produced by AveXis, a Novartis company, is a gene therapy medicine, containing the active ingredient onasemnogene abeparvovec. Zolgensma has been used for the treatment of pediatric patients with … [Read more...] about Two Zolgensma patients die of liver failure
Novartis Uses Manipulated Data to Gain Zolgensma’s FDA Approval
UNITED STATES – According to an online news article published by www.the-scientist.com, the FDA is investigating Novartis after learning that the company submitted its application for Zolgensma, a gene therapy drug, with manipulated data. Novartis Pharmaceuticals gained United States Food and Drug Administration (FDA) approval of … [Read more...] about Novartis Uses Manipulated Data to Gain Zolgensma’s FDA Approval
Manipulated Data to Gain FDA Approval of Zolgensma
Novartis Pharmaceuticals Used Manipulated Data to Gain FDA Approval of Gene Therapy Drug Novartis Pharmaceuticals, a global drug company, recently revealed that the company submitted an application to the United States Food and Drug Administration (FDA) for approval of Zolgensma, a gene therapy drug, with manipulated data. The … [Read more...] about Manipulated Data to Gain FDA Approval of Zolgensma
